By using a comprehensive analysis pipeline, we identified five potential therapeutic targets for glaucoma: two tier 1 genes (CPXM1 and FLT4), one tier 2 gene (INSR), and two tier 3 genes (CPZ and PXDN). This evidence concerns the gene FLT4 and glaucoma.